Meeting
2018 Gastrointestinal Cancers Symposium
Living with neuroendocrine tumors: Assessing quality of life (QoL) through a mobile application.
Authors
Jared Adams
Self Care Catalysts, Toronto, ON, Canada
Jared Adams , David Ray , Renee Willmon , Linda Kaleis , Anand Gautam , Sonia J. Pulgar , A. Dasari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 359)
DOI
10.1200/JCO.2018.36.4_suppl.359
Abstract #
359
Poster Bd #
G20
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors.
First Author: Jonathan R. Strosberg
Poster
2018 Gastrointestinal Cancers Symposium
Pancreatic exocrine insufficiency (PI) secondary to chronic use of long-acting (LA) somatostatin analogues (SA) in patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
First Author: Wasif M. Saif
Poster
2017 ASCO Annual Meeting
Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study.
First Author: George A. Fisher Jr.
Poster
2017 Gastrointestinal Cancers Symposium
Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III ELECT study.
First Author: Rodney F. Pommier